{"id":"NCT01373281","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia","officialTitle":"Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06-03","primaryCompletion":"2014-08-01","completion":"2017-11-21","firstPosted":"2011-06-14","resultsPosted":"2015-11-16","lastUpdate":"2022-03-21"},"enrollment":10275,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Dengue","Dengue Fever","Dengue Hemorrhagic Fever"],"interventions":[{"type":"BIOLOGICAL","name":"Live, attenuated, dengue serotype 1, 2, 3, 4 virus","otherNames":["CYD Dengue Vaccine"]},{"type":"BIOLOGICAL","name":"Placebo: Sodium chloride (NaCl) 0.9%","otherNames":[]}],"arms":[{"label":"Dengue Vaccine Group","type":"EXPERIMENTAL"},{"label":"Control Group","type":"PLACEBO_COMPARATOR"}],"summary":"The aim of the trial was to assess the efficacy of the CYD dengue vaccine in preventing symptomatic, virologically-confirmed dengue (VCD) cases.\n\nPrimary Objective:\n\nTo assess the efficacy of CYD dengue vaccine after 3 vaccinations at 0, 6, and 12 months in preventing symptomatic VCD cases, regardless of the severity, due to any of the four serotypes in children aged 2 to 14 years at the time of inclusion.\n\nSecondary Objectives:\n\n* To describe the efficacy of CYD dengue vaccine in preventing symptomatic VCD cases after the third dose to the end of the Active Phase, after at least 1 dose, and after 2 doses.\n* To describe the occurrence of serious adverse events (SAEs), including SAEs of special interest in all participants throughout the trial period.\n* To describe the occurrence of hospitalized virologically-confirmed dengue (VCD) cases and the occurrence of severe (clinically-severe or as per World Health Organization (WHO) criteria) VCD cases, throughout the Surveillance Expansion period (SEP) and throughout the trial (from Day 0 to the end of the study).\n* To describe the antibody response to each dengue serotype after Dose 2, after Dose 3, and 1 and 5 years after Dose 3.","primaryOutcome":{"measure":"Number of Symptomatic Virologically Confirmed Dengue (VCD) Cases Due to Any Serotype During the Active Phase Post-dose 3 Following Injection (Inj.) With Either CYD Dengue Vaccine or a Placebo","timeFrame":"28 days and up to 13 months post-dose 3","effectByArm":[{"arm":"CYD Dengue Vaccine Group","deltaMin":117,"sd":null},{"arm":"Placebo Group","deltaMin":133,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":12,"countries":["Indonesia","Malaysia","Philippines","Thailand","Vietnam"]},"refs":{"pmids":["25018116","27007959","26614588","26214039","26639777","27414655","28598256","28590795","27532617","27418050","27601343","29897841","35659904","34219653","34003796","33822015","33212068","29300876","28871961","27459266"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":947,"n":6848},"commonTop":["Injection Site Pain","Headache","Malaise","Myalgia","Asthenia"]}}